CDC's ACIP recommends a 2-dose vaccine series against MMR

CDC’s ACIP recommends a 2-dose vaccine series against MMR2,3

Measles cases have been on the rise—vaccination should be, too4,5

Year
2019
Confirmed cases
1,282
States affected
31
Approximately One Out of Ten 24-Month Old Children Have Been Unvaccinated Against MMR in Recent Years

Even with the rise of cases in recent years:

Nearly 1 out of 10 children were unvaccinated against MMR by 24 months of age4,5,6,7

Remember to check for children and adolescents who are unvaccinated against measles, mumps, and rubella viruses4,5

The CDC’s ACIP recommends that children complete a 2-dose vaccine series against MMR viruses with the second dose being an MMRV combination vaccine over separate injections of its equivalent component vaccines.2,3

One way M-M-R®II can be used is in a standalone series2

The First Dose of M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Should Be Given at 12-15 Months of Age

1st Dose
12–15 months of age

The Second Dose of M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Should Be Given at 4-6 Years of Age

2nd Dosea,2
4–6 years of age

aSecond dose can be administered as early as 4 weeks after the first dose.2

Catch-up vaccinations

For adults and children who are unvaccinated against MMR viruses, the CDC recommends catch-up vaccinations of a 2-dose series at least 4 weeks apart.2

M-M-R®II: Part of the MMRV Family

While M-M-R®II can be used alone in a vaccine series, it can also be used along with other vaccines in the MMRV Family to help protect your pediatric patients with one less injection.1

DISCOVER THE MMRV FAMILY

Dosage and Administration for M-M-R®II (Measles, Mumps, & Rubella Virus Vaccine Live)

Dosage and Administration

Discover the dosing regimen and administration of M-M-R®II.

Learn more
Clinical Data for M-M-R®II (Measles, Mumps, & Rubella Virus Vaccine Live)

Clinical Data

Explore the robust coverage M-M-R®II offers your pediatric patients starting after their first dose.1

See the results
ref1

Reference

  1. Marin M, Broder KR, Temte JL, et al. Centers for Disease Control and Prevention. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(3):1-12.
ref2

Reference

  1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2022. Updated February 17, 2022. Accessed March 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
ref3

Reference

  1. McLean H, Fiebelkorn A, Temte J, Wallace G; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(4):1-34.
ref4

Reference

  1. Centers for Disease Control and Prevention. Measles cases and outbreaks. Updated April 6, 2022. Accessed May 2, 2022. https://www.cdc.gov/measles/cases-outbreaks.html

ref5

Reference

  1. Ackerson B, Sy L, Glenn S, et al. Pediatric vaccination during the COVID-19 pandemic. Pediatrics. 2021;148(1):e2020047092. doi:10.1542/peds.2020-047092
ref6

Reference

  1. Hill H, Yankey D, Elam-Evans L, Singleton J, Pingali S, Santibanez T. Centers for Disease Control and Prevention. Vaccination coverage by age 24 months among children born in 2017 and 2018 – National Immunization Survey-Child, United States, 2018-2020. MMWR Morb Mortal Wkly Rep. 2021:70(41):1435-1440. http://dx.doi.org/10.15585/mmwr.mm7041a1
ref7

Reference

  1. Centers for Disease Control and Prevention. Making the vaccine decision: addressing common concerns. Updated April 27, 2022. Accessed May 2, 2022. https://www.cdc.gov/vaccines/parents/why-vaccinate/vaccine-decision.html

Indications and Usage for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

M-M-R®II is contraindicated in certain individuals, including those with: a history of

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

https://www.vaxelis.com

CANCEL
CONTINUE

Thank you for visiting.

US-MMR-00141 05/22